Tag Archives: sufferers

Hope for long Covid sufferers as Pfizer antiviral for patients left with lingering symptoms trialed

Hope for long Covid sufferers as new study will trial Pfizer’s antiviral Paxlovid in patients left with lingering symptoms months later

  • 100 people who have had long Covid symptoms for 3+ months will take Paxlovid
  • Researchers want to see if it will help with brain fog, fatigue and weakness
  • 1 in 13 US adults suffer with long Covid, and trial results are expected next year

Paxlovid – an antiviral made by Pfizer – is now being looked at as a possible long Covid treatment.

The pharma giant’s flagship Covid drug gained emergency approval in the US last December to treat high-risk patients – slashing their risk of death by 90 per cent.

It is currently the only medication you can take at home to treat Covid and has been given to millions of vulnerable Americans with underlying health conditions.

Now, researchers at Stanford are about to launch the first clinical trial of the drug to see it may also provide relief to people who are still ill months and years after clearing the virus.

Prior research has indicated that people given the drug are a quarter less likely to suffer long Covid – which most commonly causes intense tiredness, brain fog and muscle weakness. 

As of yet, there are no proven treatments for long Covid, and no one knows what causes the ongoing symptoms.

A popular theory is that there may be bits of leftover virus wreaking havoc in the body. A recent study suggested people with long Covid suffer physical alterations to their brain months after clearing the initial infection.

More than 15million Americans are officially estimated to have long Covid to varying degrees.

Trial participants will take the antiviral drug for ten days longer than people usually take it for, to see if it needs longer to work

What is long Covid? 

Long Covid is an informal term, used to describe ongoing symptoms following a Covid infection that go on longer than four weeks, according to the ONS.

A dizzying array of symptoms have been attributed to long Covid, including:

  • extreme tiredness (fatigue)
  • shortness of breath
  • chest pain or tightness
  • problems with memory and concentration (‘brain fog’)
  • difficulty sleeping (insomnia)
  • heart palpitations
  • dizziness
  • pins and needles
  • joint pain
  • depression and anxiety
  • tinnitus, earaches
  • feeling sick, diarrhoea, stomach aches, loss of appetite
  • a high temperature, cough, headaches, sore throat, changes to sense of smell or taste
  • rashes

There is no cure for the condition though the NHS does recommend a number of treatments designed to help alleviate the symptoms.

<!- - ad: https://mads.dailymail.co.uk/v8/de/health/none/article/other/mpu_factbox.html?id=mpu_factbox_1 - ->

Advertisement

The new study hopes to sign up 200 adults who have been negative for Covid for three months yet still suffer symptoms.

Half the participants will receive Paxlovid and half will take a placebo.

To treat an infection, Paxlovid is given as  six pills a day for five days, but participants in the new study will take the drug for 15 days to test the theory that the drug needs more time to have its full effect.

Results of the trial are expected next year.

The first participant in the trial was 67-year-old Bill Fimbres from California, who has been suffering with long Covid symptoms for a year-and-a-half, including a loss of smell and taste, debilitating fatigue and brain fog.

He said: ‘It’s like you have somebody else’s brain.’

Mr Fimbres will take his first dose of either the drug or placebo on Monday.

He told NBC News: ‘If I could get rid of just one of my symptoms, that would be great. I’m just going on hope.’

Evidence indicating Paxlovid might stunt long-term symptoms already exists.

A study by the Department of Veterans Affairs this month suggested those who received the drug immediately after their Covid diagnosis were 26 per cent less likely than those who did not take the antiviral to have lasting symptoms three months on. 

However, the participants were all aged 60 or above with additional health issues, meaning the findings may not be applicable to everyone. 

Long Covid has puzzled scientists and physicians since it first popped on their radar in 2020.

Its causes have not been figured out, but experts believe it could be tied to the body’s immune response to the virus. 

There have also been previously known cases of people suffering long-term symptoms after suffering more common viruses like the flu.

The CDC estimates that around 7.5 per cent of American adults are suffering from long Covid symptoms.

Sufferers are generally under the age of 50, and are more likely to be women. Reports of long Covid are most common in southern states like Kentucky and Alabama. 

Read original article here

Third week of September is worst week of the year for asthma and allergy sufferers

It’s the worst week of the year for asthma and allergy sufferers! Expert warns that third week of September is ‘peak week’ for ER visits related to the conditions as illnesses like the flu surge and pollen counts reach seasonal highs

  • Experts warn that the third week of September is ‘peak week’ for asthma and allergy complications
  • A combination of high ragweed prevalence and the start of flu season leads to a surge in doctor visits
  • Around 15% of Americans suffer from ragweed pollen allergies, which exacerbate asthma symptoms
  • Dr Robert McDermott recommends allergy sufferers to seek out care that can alleviate their symptoms

A combination of ragweed pollen and the start of flu season may make this week the worst of the year for allergy and asthma sufferers in the U.S., an experts warns.

Dr Robert McDermott, a board-certified allergist and immunologist with AllerVie, told DailyMail.com that the third week of September – between the 18th and 24th this year – is often a time where doctors report a sharp increase of allergy and asthma related visits. The period has earned the title of ‘peak week’ among experts.

This is because ragweeds, one of the most common fall allergens, reaches one of its highest pollen counts of the year in parts of America, combined with the start of flu season and the return to school around the country jump-starting the spread of infectious disease.

McDermott recommends parents who have children that suffer from asthma or severe allergies to equip a school nurse with medication their child may need incase severe symptoms arise. Adults who suffer from asthma or severe allergies may want to consult a doctor as well, as there are effective treatments available for allergies that many are totally unaware of.

The third week of September, the 18th through the 24th this year, is considered allergy ‘peak week’ by experts because of the surge of complications caused by the flu and ragweed pollen in the air (file photo)

‘Peak allergy week is the third week in September where we see the largest increase in asthma exacerbations and increased allergy symptoms in sufferers across the U.S.’ McDermott said.

The Asthma and Allergy Foundation of America reports that asthma episodes and attacks will surge throughout the month of September as multiple factors combine to cause problems for sufferers.

Ragweeds, which are prevalent along the east coast and Midwest, start to become fully grown in late August.

Dr Robert McDermott (pictured), a board-certified allergist and immunologist with AllerVie, said that he expects the flu to rebound this year after quiet seasons in recent years

By mid-to-late September, the weeds have released pollen spores into the environment en masse, causing issue for the estimated 15 percent of Americans who suffer from the allergy.

For people with asthma this situation can get even worse, as their already restricted airways may tighten. This can cause shortness of breathe, and trigger an asthma attach in the most serious of cases.

The eruption of the flu will make things worse as well. Cases of the common respiratory illness will start to pick up in the coming weeks, with late-September usually when the uptick first begins.

Combine this with schools, which have entirely returned to in-person learning across the U.S., being breeding grounds for outbreaks of the flu.

While rarely deadly, the common flu is still often dangerous for people with asthma.

It can cause the airways to become inflamed, causing them to narrow or even close – triggering asthma symptoms.

Some fear that this could be an especially problematic flu season as well, as Australia – whose flu season is during the U.S. summer months – suffered its worse flu season in a half-decade this year, with peak case rates reaching heights three times higher than usual.

McDermott says that parents should equip their child with allergy medicine and devices that can help manage their asthma if need be this week (file photo)

With the COVID-19 pandemic disrupting spread of the flu for the past two years, many do not have the necessary antibodies to fight it as easily as they did before – leading to surging cases and more serious infections.

McDermott expects the flu to roar back to usual levels in the U.S. this year as well, presenting more of a problem for asthma and allergy sufferers. 

Those at risk of more severe symptoms do not just have to accept their suffering, though.

McDermott recommends that people take active steps this week, and throughout the rest of fall to protect themselves.

For children, parents should make sure they have allergy medicine and devices like an inhaler that can treat asthma available to them at school. These can even be given to a school nurse for safe keeping.

He recommends adults to see a medical professional about treatment to manage their allergies, and make it so their immune system is less ‘hyperactive’ when exposed to inflammatory triggers like pollen.

Read original article here

Omicron Ba.5 variant: Warning over symptom of new strain that affects sufferers at night

An immunologist has warned the new strain of Covid-19 could be causing different symptoms – including one that emerges during the night.

Omicron BA.5 is a highly-contagious subvariant prompting concern as it contributes to a fresh wave of infections across the globe, including the UK.

Scientists have been finding differences with previous strains, including the ability to reinfect people within weeks of having Covid.

A leading immunologist has now suggested it could be causing a new symptom among patients.

“One extra symptom from BA.5 I saw this morning is night sweats,” Professor Luke O’Neill from Trinity College Dublin told an Irish radio station in mid-July.

“Isn’t that strange?” he added.

BA.5 is driving a surge in cases in a number of countries along with BA.4, including across Europe and in Australia. It has also become the dominant variant in the US.

“The disease is slightly different because the virus has changed,” Professor O’Neill told Newstalk.

He added: “There is some immunity to it – obviously with the T-cells and so on – and that mix of your immune system and the virus being slightly different might give rise to a slightly different diease, strangely enough night sweats being a feature.

“But very importantly, if you are vaccinated and you’re boosted, it doesn’t progress into severe disease is the message to keep reminding people.”

BA.5 was first discovered in South Africa in February, one month after BA.4 was identified in the same country.

Both have since spread around the world and sparked concern over a resurgence in Covid infections.

It comes as coronavirus cases in the UK have risen by 7 per cent to 3.8 million in the week to 14 July, up from 3.3 million a week earlier, according to Office for National Statistics data.

The increase continues to be driven by the aforementioned sub-variants, the institution said.

The latest figures represent the highest estimate since late April, but is still below the record high of 4.9 million that was reached at the end of March.

Read original article here

The Similar Stories Of COVID Long-Haulers And Chronic Lyme Sufferers

Ask Rebecca Niziol, 34, about life before Lyme, and she remembers bounding around with infinite energy. A life coach and yoga instructor, she packed her schedule with hikes, Pilates workouts, client calls, meet-ups with friends, and weekend getaways. Then, in July 2020, she felt something change.

It started with neck pain and headaches. At first, she brushed them off as side effects of sitting in a car for hours on a road trip from Chicago to Colorado to visit family. Over the next few weeks, though, she continued to develop flu-like symptoms. It was the early months of the pandemic, so her immediate thought was COVID. But tests kept coming back negative.

She couldn’t practice yoga for a month. “I was in bed 20 hours a day,” she says. Her doctor suspected loneliness and pandemic-related anxiety, but her gut told her this was different. Something more physical, never-ending. She wouldn’t learn that she was battling Lyme disease for more than a year, when she connected with a “Lyme-literate” doctor and her labs confirmed it.

Brittany Barry, of Utah, faced a similarly confusing crisis last summer. Given that she was a self-described “healthy, fit, 32-year-old woman” at the time, doctors chalked up the muscle aches, fatigue, and shortness of breath to long COVID—a term for the phenom of health problems continuing long after someone tests positive for the virus. (She had COVID in February 2021.) One MD blamed post-pregnancy changes, while another told her to see a counselor.

Fast-forward to January 2022, when she found a doctor who did blood work that pointed to Lyme that had likely gone undetected for years.

Getty

Parallel Experiences

A coincidence that these women’s diagnoses came when they did? Maybe. But just like Niziol and Barry, many who’ve been impacted by long COVID, Lyme, or even both in the past few years are realizing they’re telling a similar story. There’s been a shift in empathy for chronic-illness and autoimmune patients who are stuck in a cycle of nonspecific symptoms that medical experts don’t totally know what to do with, says Niziol, who is still managing Lyme today.

Despite many yet-to-be-solved mysteries (we’ll get into those!), physicians and patients alike can agree the suffering is real—as is the serious change in perspective, says Robert Kalish, MD, a rheumatologist and the director of the Lyme Disease Clinic at Tufts Medical Center. “The pandemic helped people grasp the idea that you can get an infection, kill the initial cause, and still suffer lasting consequences from damage that’s been done—even if it’s difficult to detect or understand,” he says.

Up to 20 percent of Lyme patients report that their symptoms come back or never truly go away.

When you’re sick, you crave validation. Recognition gives you a better chance at care, not to mention dignifies your reality. “There’s a lot of similarity in experience between long-haulers and folks with chronic illnesses like mine being misunderstood or misdiagnosed,” Niziol says. “I might not have what you have, but I relate and deeply empathize.”

Diagnosis Dilemma

More compassion is huge. But it doesn’t erase the fact that Lyme is the most common tick-borne infection in the U.S., with an estimated 476,000 new cases each year (although only an estimated 35,000 get reported annually because of how difficult it is to diagnose). Since 1991, the prevalence of Lyme has nearly doubled as deer ticks, the main carriers of the disease, have expanded their territory. What’s more, increasing temps are expected to up Lyme cases by more than 20 percent between 2036 and 2065, a recent study found.

So, yes, a very real and growing threat, yet Lyme has been steeped in controversy pretty much since it was discovered in the ’70s. For one thing, there’s no perfect test: False negatives and positives happen often, which makes getting a correct diagnosis a challenge. Not every positive person shows the one telltale symptom—a bull’s-eye–shaped rash—either. (Niziol and Barry have no recollection of one.)

Further complicating the path to an accurate diagnosis is that Lyme, nicknamed “the great imitator,” can look like a bunch of other conditions, such as multiple sclerosis, depression, fibromyalgia, or a general viral infection. Niziol faced multiple misdiagnoses as her symptoms escalated to brain fog, blurry vision, bouts of numbness in limbs, and gaps in memory, as the months rolled on without answers. “I felt like a shell of a human,” she says. “My vibrancy was gone; joy left my body.”

Getty

Long-Haul Life

If and when you get a definitive read? The fight doesn’t necessarily stop there. With speedy detection and treatment (typically a four-week or longer course of antibiotics), the infection is usually easy to resolve at first. But for many, including Niziol, symptoms live on.

In August 2021, just over a year after her symptoms first emerged, and still desperate to find a doctor who really understood, she searched online for specialists in her area. This time, she visited Casey Kelley, MD, a family and integrative medicine physician. Dr. Kelley ran a slew of tests and diagnosed Niziol with chronic Lyme. (Just when you thought things couldn’t get trickier!)

The diagnosis most commonly given is post-treatment Lyme disease syndrome, or PTLDS. But some doctors go so far as to use the term “chronic Lyme disease,” though this is not a diagnosis recognized by the National Institutes of Health. That’s because in one camp, you have pros who question the legitimacy of this term that indicates an ongoing infection, citing human studies that show meds are effective in killing bacteria that cause Lyme. On the other side are docs like Dr. Kelley who believe chronic Lyme is real even if it’s unclear why it happens. (She points to studies that suggest a long-term infection remains.)

Whatever you call it, “This much is not controversial: There’s no proven effective treatment for persistent Lyme,” says Linden Hu, MD, a professor of immunology at Tufts University School of Medicine. Depending on your doctor, solutions could involve meds, supplements, and/or an anti-inflammatory diet. “A two-steps-forward, one-slide-back kind of situation,” Niziol says.

Maria Fuchs / Getty

Health On The Horizon

The reassuring news is that real advancement is underway. In the past few years, tens of millions of dollars have been dedicated to combating Lyme. Researchers at Columbia University are working on brain imaging studies to better understand symptoms like chronic fatigue and pain that come with the infection.

Game-changing innovations to defeat the disease are also in the pipeline. A vaccine being tested in guinea pigs (thank you, Yale researchers) triggers an immune reaction to a tick bite that helps get the bug to detach, inhibits its ability to feed from you, and reduces transmission of the pathogen. Another candidate, from Valneva and Pfizer, works by killing bacteria in the bloodsuckers. Early studies indicate the prick is safe, and you might be able to get it as soon as 2025.

Researchers at Tufts University also set the lofty goal of eradicating Lyme by 2030. “The best chance for making sure no one gets Lyme is to hit it where it lives—in the mice, birds, and ticks in the wild,” says Dr. Hu, who is co-director of the initiative. His team is testing a bait-delivered drug that targets Lyme in wild mice in Massachusetts, followed by sites in other states, to have all key target areas covered within the next five years.

    And progress for one chronic illness means progress for others. Long COVID patients are being treated with many of the same interventions that have worked for persistent Lyme symptoms. The similarities in how these diseases impact the immune system are becoming evident, Dr. Kelley says. “The patient awareness and advocacy will continue to grow from here,” she says. “We’re going to see new preventive measures to help people get their lives back faster.”One-on-one connections with people with a persistent illness (Lyme, long COVID, MS, you name it) can be a saving grace, adds Niziol. She exchanged DMs via Instagram with people who helped her find podcasts and advocacy groups. Months into treatment, Niziol is pushing herself to stay active again and remains optimistic. “I’m not going to ignore the hard parts or minimize them,” she says. “But with more understanding, more empathy, there is hope.” Right on.

      This article originally appeared in the July/August 2022 issue of Women’s Health.


      Lauren Krouse is a freelance writer who covers health, domestic violence, and self-advocacy.

      This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

      Read original article here

      Vaccine trial gives hope to pancreatic cancer sufferers | News

      A pioneering vaccine developed using the same mRNA technology as Covid jabs has raised hopes of a cure for pancreatic cancer.

      Half of patients given the vaccine, designed to prevent cancer returning after surgery, remained free of the disease 18 months later.

      The vaccine was developed by US scientists in collaboration with BioNTech, the German firm behind the Pfizer coronavirus jab.

      The cancer vaccine uses the same mRNA technology used by BioNTech to create the Pfizer coronavirus jab

      GETTY IMAGES

      Pancreatic cancer is the deadliest common cancer, with 90 per cent of patients dying within two years of diagnosis.

      It kills 10,000 a year in the UK — similar to the number who die from breast cancer — and there has been no improvement in survival rates or treatment breakthroughs for decades.

      But a groundbreaking trial, presented at the American Society of Clinical

      Read original article here

      Drug offers instant relief for thousands of migraine sufferers | News

      Thousands of Britons who suffer from chronic migraines could benefit from a drug found to relieve previously untreatable headache pain.

      Nine in ten patients with debilitating migraines reported immediate pain relief after receiving an infusion of a local anaesthetic called lidocaine. Researchers believe that it could “break the cycle of pain” experienced by sufferers.

      There is no cure for migraines, which affect six million people in Britain, although patients may be prescribed painkillers or Botox injections to ease symptoms. Migraines are the second leading cause of work absence, costing the economy £2.25 billion a year.

      About one in 1,000 people suffer chronic migraines, meaning they get headaches at least 15 days a month. The new study said lidocaine appeared to be suitable for such patients,

      Read original article here

      Research Is Bad News for Allergy Sufferers


      (Newser)

      By century’s end, if worse-case models prove accurate, pollen season could start 40 days earlier and last 19 days longer than it does now. For many people, that means two extra months of sneezes, runny noses, hives, and itchy eyes. For people with asthma, it means more shortness of breath, more wheezing, and the need for more medicines and therapies. According to a recent peer-reviewed study published in Nature Communications, this is an ongoing 30-year trend toward longer, more intense pollen seasons.

      Per NBC News, “using historical pollen data and predictive climate models, the researchers were able to paint a picture of how and when plants and trees could release pollen in the coming decades.” Lead author Yingxiao Zhang of the University of Michigan explained that increased levels of carbon dioxide can boost pollen output in two ways. First and foremost, carbon and other greenhouse gases are raising temperatures on the planet, and scientists know warmer temperatures can accelerate pollen production. Also, bigger plants tend to produce more pollen, and the more water and carbon dioxide plants get, the more they can gorge themselves on sugars derived through photosynthesis.

      NBC also points to EPA research showing variations from one place to another, with northern states seeing some of the biggest changes so far, as in Minnesota and North Dakota, where “ragweed season lengthened by 21 days from 1995 to 2015.” Allergy symptoms vary from person to person, as well, and those who don’t suffer now aren’t necessarily in the clear forever. An allergy doctor interviewed on NBC’s Today show said everyone’s immune system responds a little differently to different pollens, and environmental factors can change how allergy cells react to various pollens. For relief, experts suggest shopping around for an effective antihistamine because individuals may respond differently to those, too. An NIH study says standard medical masks used to control the spread of COVID are effective at filtering pollen. (Read more pollen stories.)

      var FBAPI = '119343999649';

      window.fbAsyncInit = function() { FB.init({ appId: FBAPI, status: true, cookie: true, xfbml: true, oauth: true, authResponse: true, version: 'v2.5' });

      FB.Event.subscribe('edge.create', function (response) { AnalyticsCustomEvent('Facebook', 'Like', 'P'); }); };

      // Load the SDK asynchronously (function (d, s, id) { var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));



      Read original article here

      Covid sufferers become infectious quicker than first thought, study shows

      The world’s first study in which volunteers were deliberately infected with Covid-19 found that people started to develop symptoms and become infectious to others after just two days, much quicker than expected.

      Scientists had previously estimated this incubation period to be five days.

      The UK government-funded “human challenge” trial found that levels of the Sars-Cov-2 virus in the nose and throat peaked after five days, though participants remained infectious for an average of nine days and a maximum of 12 days after exposure.

      The researchers said their results support guidance that people should quarantine for 10 days after they first feel Covid symptoms or have a positive test result.

      The study took place in a special unit at the Royal Free Hospital in London. Eighteen of the 34 volunteers aged 18 to 29 became infected after receiving a low dose of the original Sars-Cov-2 strain via droplets in the nose.

      None suffered serious symptoms though 13 temporarily lost their sense of smell. Only one volunteer still had that symptom after six months.

      “Our study reveals some very interesting clinical insights, particularly around the short incubation period of the virus and extremely high viral shedding from the nose,” said Christopher Chiu, professor in infectious diseases at Imperial College London, who was the trial’s chief investigator.

      Eighteen of the 34 volunteers who took part in the study became infected after receiving a low dose of the original Sars-Cov-2 strain via droplets in the nose © Jacob Hopkins

      The trial was a partnership between Imperial, the Royal Free and hVivo, a company specialising in human challenge studies that is part of the London-listed Open Orphan company.

      Participants started to develop symptoms within two days of being given a tiny nasal dose (10 micrograms) of the virus. High levels of viral infection appeared first in the throat and almost immediately afterwards in the nose.

      Levels peaked after five days, by which point the nose was the main site of infection. The researchers said the findings highlighted the importance of wearing face masks covering both mouth and nose.

      Lateral flow tests were also shown to be a good indicator of whether someone was infectious.

      “We found that overall, lateral flow tests correlate very well with the presence of infectious virus,” said Chiu. “Even though in the first day or two they may be less sensitive, if you use them correctly and repeatedly, and act on them if they read positive, this will have a major impact on interrupting viral spread.”

      His Imperial colleague Professor Wendy Barclay said that, although 10 days of self-isolation was good guidance in the absence of testing, the results supported cutting that to five days followed by negative lateral flow test results on two consecutive days.

      The study was initially launched to help test experimental vaccines, before Pfizer and BioNTech announced they had developed an effective jab in late 2020.

      Jonathan Van-Tam, England’s deputy chief medical officer, said it had provided more “key data” on the virus, while further human challenge trials could be used to accelerate the development of other Covid vaccines and antiviral drugs.

      Andrew Catchpole, chief scientist at hVivo, said that although the study focused on the original Sars-Cov-2 strain, and there are differences in transmissibility between it and the other variants, “the same factors will be responsible for protection against it, meaning the findings remain valuable for variants such as Delta or Omicron”.

      Open Orphan said it was developing a Delta strain of the virus with Imperial that could be used in future trials.

      Read original article here

      Long Covid sufferers may have hidden damage to their lungs, new MRI scan study reveals

      Long Covid sufferers may have hidden lung damage, a small study in the UK has suggested.

      Scientists supported by the Oxford Biomedical Research Centre used a xenon gas scan to pick up abnormalities in the lungs of those suffering from breathlessness after having Covid.

      The study uses the odourless, colourless, tasteless and chemically non-reactive gas, to investigate possible lung damage in the patients who have not been admitted to hospital, but continue to experience the symptom.

      The initial results of the study suggest there is significantly impaired gas transfer from the lungs to the bloodstream in the long Covid patients despite other tests – including CT scans – coming back as normal.

      The lungs of a healthy patient (left) and that of a Long Covid sufferer (right) in the study 

      A larger study has been commissioned to confirm the results of this small sample.

      Lead researcher Dr Emily Fraser told the BBC the study had been borne out of frustration of medical professionals who could not find clinical reasons for the breathlessness using X-rays and CT scans.

      Dr Fraser said: ‘This is important research and I really do hope this will shed more light on that.

      ‘It is important people know that rehabilitation strategies and breathing retraining can be really helpful.

      ‘When we see people in clinic who are breathless we can make progress.’

      The method and clinical applications were developed by Professor Jim Wild and the Pulmonary, Lung and Respiratory Imaging Sheffield (Polaris) research group at the University of Sheffield.

      Prof Wild said: ‘Xenon follows the pathway of oxygen when it is taken up by the lungs and can tell us where the abnormality lies between the airways, gas exchange membranes and capillaries in the lungs.’

      Co-chief investigator of the study, Prof Fergus Gleeson, told the BBC: ‘There are now important questions to answer, such as, how many patients with long Covid will have abnormal scans, the significance of the abnormality we’ve detected, the cause of the abnormality, and its longer-term consequences.

      ‘Once we understand the mechanisms driving these symptoms, we will be better placed to develop more effective treatments.’ 

      Xenon gas is visible on scans unlike oxygen which means it can be used to track how well lungs are moving the gas around the body.

      Gas transfer was noticeably less effective in the Long Covid patients than their healthy counterparts.

      The paper has not yet been peer-reviewed and thus should be treated with skepticism.

      The ONS calculates 506,000, 40 per cent, have suffered the wide-ranging condition called Long Covid for over a year.

      The estimates are based on a survey of 350,000 people who self-reported suffering with Long Covid, meaning they were not necessarily diagnosed.

      These responses were collected in the four weeks to December 6, before the recent surge in Covid infections driven by the Omicron variant.

      Britain’s Covid cases continued to fall today by 5.3 per cent in a week, official figures show as the Omicron wave recedes across the country.

      UK Health Security Agency (UKHSA) data show there 72,727 positive tests over the last 24 hours, down from the 76,807 recorded last week.

      It was the fifth day in a row cases have fallen — after briefly picking up on Sunday and Monday. However, the UK-wide figures do not include cases in Scotland today so the actual drop-off is may not be as steep as it appears.

      The number of people dying with the virus also continued to fall slightly today, reducing 0.3 per cent to 296 from the 297 recorded last week.

      The figures come after thousands of punters took to dance floors across England without needing to show Covid passes or use masks for the first time since Plan B measures were brought to an end last night.

      Revellers packed out clubs, bars and pubs across England for boozy celebrations yesterday evening as the nation fully embraced its first weekend of partying without Plan B measures in place.

      WHAT IS LONG COVID?

      As of December 2021, 506,000 people in the UK were estimated to have long Covid, according to the NHS.

      Long Covid is an informal term, used to describe ongoing symptoms following a Covid infection that go on longer than 12 weeks.  

      A dizzying array of symptoms have been attributed to long Covid, including: 

      • extreme tiredness (fatigue)
      • shortness of breath
      • chest pain or tightness
      • problems with memory and concentration (‘brain fog’)
      • difficulty sleeping (insomnia)
      • heart palpitations
      • dizziness
      • pins and needles
      • joint pain
      • depression and anxiety
      • tinnitus, earaches
      • feeling sick, diarrhoea, stomach aches, loss of appetite
      • a high temperature, cough, headaches, sore throat, changes to sense of smell or taste
      • rashes

      There is no cure for the condition though the NHS does recommend a number of treatments designed to help alleviate the symptoms.

      Read original article here

      Allergy sufferers have nearly 40% lower risk of COVID-19 infection, study says

      People who suffer from allergic conditions have a lower risk for developing COVID-19, according to a new U.K. study.

      The research from the Queen Mary University of London was published Thursday in the journal Thorax.

      ‘LONG’ COVID CAUSES BAD SMELLS AND TASTES, DEPRESSION FOR SOME SURVIVORS: ‘HOT WATER SMELLS LIKE ROTTING MEAT’

      Analyzing data from more than 16,000 adults between May 1, 2020, and Feb. 5, 2021, the authors asked participants to provide information about their age, household circumstances, job, lifestyle, weight, height, longstanding medical conditions, medication use, vaccination status and diet and supplement intake upon enrollment in the study in an online questionnaire.

      Monthly follow-up questionnaires captured incident COVID-19 and the researchers used logistic regression models to estimate the associations between potential risk factors and the odds of developing COVID-19.

      A woman sneezes
      (Credit: iStock)

      15,227 people – with the majority women and nearly 95% who identified their ethnic origin as White – filled out at least one follow-up questionnaire and 14,348 people completed the final questionnaire. The average age of the participants was 59.

      In total, 446 cases of coronavirus were recorded, or nearly 3% of participants. Thirty-two people were admitted to the hospital.

      Those with atopic diseases like eczema and those with hay fever or rhinitis had a 23% lower risk of contracting the disease. 

      Including people who suffer from asthma, there was a 38% lower risk of infection – even after accounting for the use of steroid inhalers.

      MORE AMERICAN ADULTS LIVING ALONE, CENSUS BUREAU REPORTS

      Taking immunosuppressants was also associated with 53% lower odds of infection, although the authors noted this statistic may reflect greater shielding from infection by these patients.

      Contrary to past studies, the researchers found that older age, male sex and other underlying conditions were not linked to a higher risk of infection,

      Alternatively, people of Asian and Asian British ethnicity, household overcrowding, socializing indoors with other households, holding a front-line occupation excluding health and social care and raised body mass index or obesity were independently associated with a heightened risk.

      Adults who were Asian or Asian British had twice the risk of testing positive compared with White U.K. adults and the greater the number of people sharing a household and the higher the number of visits made to indoor public places, the higher the odds of getting COVID-19.

      The researchers said the study shows that there is limited overlap between risk factors for developing COVID-19 and those for ICU admission and death, as reported in hospitalized cohorts.

      They also note that the study is observational and cannot establish cause.

      CLICK HERE TO GET THE FOX NEWS APP

      Other limitations include that there was no oversight of COVID-19 swab testing and the reliance on results of testing usually prompted by symptoms – potentially missing asymptomatic SARS-CoV-2 infection.

      In addition, ethnic minorities were underrepresented in the study.

      Read original article here